ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,079Medicare Part D Prescriptions Filled, Including Refills

Rank: 338 out of 1000

$392K Total Retail Price of All Prescriptions

Rank: 359 out of 1000

217 Patients Receiving at Least One Drug in Part D
46%Patients 65 Years and Older
82% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Alabama
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 217 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

29% of this provider’s 217 patients filled at least one prescription for a schedule three drug, compared to an average of 20%.

Risky Drugs to Seniors

3% of this provider’s 4,357 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$49 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

37 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Alabama
HYDROCHLOROTHIAZIDE 356 201 1 9
OMEPRAZOLE 351 220 2 2
HYDROCODONE-ACETAMINOPHEN 307 142 S3 3 1
CARVEDILOL 277 165 4 15
ENALAPRIL MALEATE 211 158 5 58
METFORMIN HCL 203 103 6 8
SIMVASTATIN 190 141 7 3
FUROSEMIDE 189 115 8 7
ATORVASTATIN CALCIUM 185 115 9 18
AMLODIPINE BESYLATE 183 113 10 6
GABAPENTIN 175 69 11 11
LISINOPRIL 161 97 12 5
LEVOTHYROXINE SODIUM 157 102 13 4
LOSARTAN POTASSIUM 155 68 14 25
CRESTOR 134 97 15 30
MELOXICAM 127 47 16 14
POTASSIUM CHLORIDE 115 49 17 10
GLYBURIDE 113 60 R 18 92
NEXIUM 104 31 19 23
TRAMADOL HCL 98 44 20 13
LOVASTATIN 92 47 21 41
RANITIDINE HCL 82 53 22 37
ZOLPIDEM TARTRATE 66 45 23 16
CLONIDINE HCL 66 39 23 27
FLUOXETINE HCL 66 21 23 51
ESCITALOPRAM OXALATE 64 43 26 60
DIGOXIN 64 64 26 52
ALLOPURINOL 61 43 28 31
FAMOTIDINE 59 37 29 88
CLOPIDOGREL 58 32 30 35
CYCLOBENZAPRINE HCL 57 17 R 31 39
SERTRALINE HCL 55 23 32 26
LIPITOR 55 43 32 170
INSULIN SYRINGE 54 24 34 93
DIOVAN 53 32 35 67
FOSINOPRIL SODIUM 52 31 36 154
NIASPAN 50 39 37 172
DEXILANT 50 24 37 248
NIFEDIPINE ER 50 36 37 130
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 13, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.